TNFRSF4 and melanoma: Additionally, OX40 agonist engagement in the setting of chemotherapy-induced lymphopenia with adoptively transferred tumor-specific CD4+ T cells was effective in treating B16 melanomas and chimeric B16:B78H1 melanomas (23).